Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Autor: Bhatt, Dl, Szarek, M, Pitt, B, Cannon, Cp, Leiter, La, Mcguire, Dk, Lewis, Jb, Riddle, Mc, Inzucchi, Se, Kosiborod, Mn, Cherney, Dzi, Dwyer, Jp, Scirica, Bm, Bailey, Cj, Díaz, R, Ray, Kk, Udell, Ja, Lopes, Rd, Lapuerta, P, Steg, Gabriel, P, Lauro, D

Publikováno v: Bhatt, D L, Szarek, M, Pitt, B, Cannon, C P, Leiter, L A, McGuire, D K, Lewis, J B, Riddle, M C, Inzucchi, S E, Kosiborod, M N, Cherney, D Z I, Dwyer, J P, Scirica, B M, Bailey, C J, Díaz, R, Ray, K K, Udell, J A, Lopes, R D, Lapuerta, P, Steg, P G & SCORED Investigators 2021, ' Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease ', The New England Journal of Medicine, vol. 384, no. 2, pp. 129-139 . https://doi.org/10.1056/NEJMoa2030186
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

In a trial involving 10,584 patients with diabetes and chronic kidney disease, sotagliflozin resulted in fewer total deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo. Diarrhea, my

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9705eeadc025b1e0478507d16cdaa4
https://pure.au.dk/portal/da/publications/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease(6bc50c6b-8a7a-4eea-bd9e-9032680e8b64).html

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum

Autor: Cefalu, Wt, Buse, Jb, DEL PRATO, Stefano, Home, Pd, Leroith, D, Nauck, Ma, Raz, I, Rosenstock, J, Riddle, Mc

Publikováno v: Diabetes Care

The trend toward personalized management of diabetes has focused attention on the differences among available pharmacological agents in terms of mechanisms of action, efficacy, and, most important, safety. Clinicians must select from these features t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::731e86f0784eda4e80e41c0dd7c4568f
https://pubmed.ncbi.nlm.nih.gov/25147257

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

Autor: ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-bli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::0352fc007e491bd3e81a4427858fcd06
https://www.bib.irb.hr/712281

Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine

Autor: Riddle Mc

Publikováno v: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 28(9)

Whether a sulfonylurea may be used together with insulin for treating NIDDM has been controversial. One view, based on older studies, has been that the additional benefit is too small or the level of glucose control achieved usually too poor to recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d8d64b7780fe20584e8eb2b240ef62
https://pubmed.ncbi.nlm.nih.gov/8911978

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.